Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L
Department of Gynecology and Obstetrics, University Ulm, Ulm.
Department of Mathematics and Computer Science, University Bremen, Bremen.
Ann Oncol. 2014 Mar;25(3):628-632. doi: 10.1093/annonc/mdt584. Epub 2014 Feb 9.
Radiotherapy (RT) is proven to be an important backbone for adjuvant therapy in randomized, controlled trials, but it is unclear if these effects are provable in a daily routine cohort of breast cancer patients. This study sought to answer the following questions in a daily routine cohort of breast cancer patients: 1. Does guideline-adherent RT improve primary breast cancer patient survival? 2. Is breast-conserving surgery (BCS) followed by RT equal to a mastectomy (MA) with regard to outcome parameters? 3. Does adjuvant RT compensate for an incomplete tumor resection (R1)?
In this retrospective, multicenter cohort study, we investigated data from 8935 primary breast cancer patients recruited from 17 participating certified breast cancer centers in Germany between 1992 and 2008. Guideline adherence based on internationally validated guidelines.
The patients who received guideline-adherent RT for primary breast cancer were associated with significantly improved survival parameters [recurrence-free survival (RFS): P < 0.001; overall survival (OS): P < 0.001] compared with patients who did not receive guideline-adherent adjuvant RT. Furthermore, the results demonstrated that there were no significant differences in RFS and OS between BCS followed by RT and MA [RFS: P = 0.293; OS: P = 0.104]. Adjuvant RT did not improve the outcome of patients receiving nonguideline-adherent incomplete tumor resection via BCS (R1); these patients showed a significantly impaired RFS [P < 0.001] and OS [P < 0.001] compared with patients who underwent guideline-adherent complete tumor resection via BCS (R0). In addition, non-guideline-adherent RT after MA (overtherapy) did not significantly influence survival [RFS: P = 0.838; OS: P = 0.613].
Our study confirms the importance of guideline-adherent adjuvant RT. It shows highly significant associations between RFS or OS and guideline adherent RT. Nevertheless, inadequate (R1-) surgical resection in a daily routine cohort of patients increases the risk of local recurrence and appears not to be compensated by the following RT.
在随机对照试验中,放射治疗(RT)被证明是辅助治疗的重要支柱,但在乳腺癌患者的日常队列中这些效果是否可证尚不清楚。本研究旨在在乳腺癌患者的日常队列中回答以下问题:1. 遵循指南的放疗能否提高原发性乳腺癌患者的生存率?2. 保乳手术(BCS)后进行放疗与乳房切除术(MA)在结局参数方面是否相当?3. 辅助放疗能否弥补肿瘤切除不完全(R1)的情况?
在这项回顾性多中心队列研究中,我们调查了1992年至2008年间从德国17个参与的认证乳腺癌中心招募的8935例原发性乳腺癌患者的数据。遵循基于国际验证指南的标准。
与未接受遵循指南的辅助放疗的患者相比,接受原发性乳腺癌遵循指南放疗的患者的生存参数显著改善[无复发生存期(RFS):P < 0.001;总生存期(OS):P < 0.001]。此外,结果表明,BCS后放疗与MA之间的RFS和OS无显著差异[RFS:P = 0.293;OS:P = 0.104]。辅助放疗并未改善通过BCS接受非遵循指南的不完全肿瘤切除(R1)的患者的结局;与通过BCS接受遵循指南的完全肿瘤切除(R0)的患者相比,这些患者的RFS[P < 0.001]和OS[P < 0.001]显著受损。此外,MA后非遵循指南的放疗(过度治疗)对生存无显著影响[RFS:P = 0.838;OS:P = 0.613]。
我们的研究证实了遵循指南的辅助放疗的重要性。它显示了RFS或OS与遵循指南的放疗之间高度显著的关联。然而,在日常患者队列中手术切除不足(R1 -)会增加局部复发的风险,且后续放疗似乎无法弥补这一风险。